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Abstract
AIM: To investigate the evolution of disease phenotype 
in adult and pediatric onset Crohn’s disease (CD) popu-
lations, diagnosed between 1977 and 2008. 
METHODS: Data of 506 incident CD patients were 
analyzed (age at diagnosis: 28.5 years, interquartile 
range: 22-38 years). Both in- and outpatient records 
were collected prospectively with a complete clini-
cal follow-up and comprehensively reviewed in the 
population-based Veszprem province database, which 
included incident patients diagnosed between January 
1, 1977 and December 31, 2008 in adult and pediatric 
onset CD populations. Disease phenotype according 
to the Montreal classification and long-term disease 
course was analysed according to the age at onset in 
time-dependent univariate and multivariate analysis.
RESULTS: Among this population-based cohort, 
seventy-four (12.8%) pediatric-onset CD patients were 
identified (diagnosed ≤ 17 years of age). There was 
no significant difference in the distribution of disease 
behavior between pediatric (B1: 62%, B2: 15%, B3: 
23%) and adult-onset CD patients (B1: 56%, B2: 21%, 
B3: 23%) at diagnosis, or during follow-up. Overall, the 
probability of developing complicated disease behaviour 
was 49.7% and 61.3% in the pediatric and 55.1% and 
62.4% in the adult onset patients after 5- and 10-years 
of follow-up. Similarly, time to change in disease behav-
iour from non stricturing, non penetrating (B1) to com-
plicated, stricturing or penetrating (B2/B3) disease was 
not significantly different between pediatric and adult 
onset CD in a Kaplan-Meier analysis. Calendar year of 
diagnosis (P  = 0.04), ileal location (P  < 0.001), perianal 
disease (P  < 0.001), smoking (P  = 0.038) and need 
for steroids (P  < 0.001) were associated with presence 
of, or progression to, complicated disease behavior at 
diagnosis and during follow-up. A change in disease 
location was observed in 8.9% of patients and it was 
associated with smoking status (P = 0.01), but not with 
age at diagnosis. 
BRIEF ARTICLE
CONCLUSION: Long-term evolution of disease behav-
ior was not different in pediatric- and adult-onset CD 
patients in this population-based cohort but was associ-
ated to location, perianal disease and smoking status. 
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
Inflammatory bowel disease (IBD) is multifactorial: both 
genetic and environmental risk factors (e.g., smoking, or 
appendectomy) contribute to its pathogenesis[1]. Dur-
ing the past two decades, the incidence pattern of  IBD 
has changed significantly[2], showing both common and 
distinct characteristics. The phenotypic classification of  
Crohn’s disease (CD) plays an important role in patient 
management, and may help predict the clinical course 
in CD patients[3]. In 2005, the Montreal revision of  the 
Vienna classification system was introduced[4]. Although 
the broad categories for CD classification remained the 
same, changes were made within each category. Upper 
gastrointestinal (GI) disease is now classified indepen-
dently of, or alongside, disease at more distal locations. 
Finally, perianal disease, which occurs independently of  
small bowel fistulae, is no longer classified as penetrating 
disease. Instead, a perianal modifier has been introduced, 
which may coexist with any disease behavior. 
Using the Vienna classification system, it has been 
shown in clinical cohorts that there can be a significant 
change in disease behavior over time, whereas disease 
location remains relatively stable[3,5]. In a landmark pa-
per by Cosnes et al[6], up to 70% of  CD patients devel-
oped either penetrating or stricturing disease. Louis et 
al[5] reported similar results in a Belgian study, in which 
45.9% of  patients had a change in disease behavior (P 
< 0.0001) during 10 years of  follow-up, especially from 
non-stricturing, non-penetrating disease to either stric-
turing (27.1%; P < 0.0001) or penetrating (29.4%; P < 
0.0001) forms. Age at diagnosis (before or after age 40) 
had no influence on either disease location or behavior. 
In contrast, disease location remained relatively stable 
during follow-up, with only 15.9% of  patients exhibiting 
a change in disease location during the first 10 years. In 
addition, the probability of  change in disease behavior 
in patients with initially non-stricturing, non-penetrating 
disease was 30.8% over nine years in a more recent Hun-
garian study[7], in which data were obtained from referral 
centers.
More recently, authors from New Zealand[3] showed 
in a population-based cohort study, that although > 70% 
percent of  CD patients had inflammatory disease at di-
agnosis, 23% and 40% of  patients with initial inflamma-
tory disease progressed to complicated disease pheno-
types after five and ten years of  follow-up, respectively. 
This was not associated with age at onset. In contrast, 
disease location remained stable in 91% of  patients with 
CD. Of  note however, the median follow-up of  CD pa-
tients was only 6.5 years. Similarly, in the IBSEN cohort, 
36%, 49% and 53% of  CD patients diagnosed between 
1990 and 1994 initially had or developed either strictur-
ing or penetrating complications[8]. In addition, recent 
data suggest a change in the natural history of  CD as 
shown by decreasing surgical rates[9].  
According to the available literature, pediatric onset 
CD runs a more aggressive course, including more ex-
tensive disease location, more upper GI involvement, 
growth failure, more active disease, and need for more 
aggressive medical therapy, in predominantly referral-
center studies[10-12]. However, data so far have been partly 
contradictory, and pediatric disease behavior seems to 
parallel that of  adults[13]. A Scottish study simultaneously 
compared disease behavior and location in pediatric and 
adult onset IBD patients[14]. In childhood-onset patients, 
there was a clear difference in disease location at onset 
and after five years; with less ileum- and colon-only loca-
tion among pediatric-onset patients, but more ileocolon-
ic and upper gastrointestinal involvement (P < 0.001 for 
each). In addition, disease behavior after five years did 
not differ between the two groups. In contrast, disease 
phenotype was associated with location. However, the 
evolution of  disease phenotype was not studied. 
Because only limited data are available on the evolu-
tion of  disease phenotype in patients with a pediatric- 
and adult-onset CD in from a single population-based 
cohort over a long-term follow-up, the aim of  this study 
was to analyze the evolution of  disease behavior and 
location in a population-based Veszprem province da-
tabase according to the age-group at diagnosis, which 
included incident adult- and pediatric-onset CD popula-
tions diagnosed between January 1, 1977 and December 
31, 2008.
MATERIALS AND METHODS
Patients
A well-characterized Hungarian cohort of  1420 incident 
cases of  inflammatory bowel disease diagnosed between 
January 1, 1977 and December 31, 2008 were included. 
In total, 506 CD patients [CD, male: female: 251:255, age 
at diagnosis: 28.5 years, interquartile range (IQR): 22-38 
years] were diagnosed during the inclusion period. Pa-
tients were followed until December 31, 2009 or death. 
All patients had at least one year of  follow-up data avail-
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able. Patients with indeterminate colitis at diagnosis were 
excluded from the analysis. Patient clinical data is sum-
marized in Table 1. The ratio of  urban-to-rural residence 
was also relatively stable (55% urban). 
Methods
Data collected from 7 general hospitals and gastroenter-
ology outpatient units (Internal Medicine Departments, 
Surgery Departments, Paediatric Departments and Out-
patient Units) from Veszprem County (Veszprem, Papa, 
Tapolca, Ajka, Varpalota, Zirc). A more detailed descrip-
tion of  the data collection and case assessment methods 
used, as well as the geographical and socioeconomic 
background of  the province and the Veszprem Province 
IBD Group was published in previous epidemiological 
studies by this group[15]. 
The majority of  patients (94% of  CD and 71% of  
ulcerative colitis patients) were monitored at the Csol-
noky F Province Hospital in Veszprem. This hospital 
also serves as a secondary referral center for IBD pa-
tients in the province. Data collection was prospective 
since 1985; prior to that, only in Veszprem were data 
collected prospectively. In other sites throughout the 
province, data for this period (1977-1985) were col-
lected retrospectively in 1985. Both in- and outpatients 
permanently residing in the area were included in the 
study. Diagnoses (based on hospitalization records, out-
patient visits, endoscopic, radiological, and histological 
evidence) generated in each hospital and outpatient unit 
were reviewed thoroughly, using the Lennard-Jones[16] 
or the Porto criteria[17], as appropriate. At the Veszprem 
pediatric IBD clinic, all probable cases of  IBD are evalu-
ated in a single unit by a pediatric gastroenterologist 
with experience in the diagnosis and treatment of  IBD 
together with adult gastroenterologists. In addition, all 
endoscopies for pediatric patients are performed and all 
follow-up is conducted by two expert adult gastroenter-
ologists, and pediatric cases were followed together by 
pediatric and adult gastroenterologists. According to the 
Montreal classification, an age at diagnosis < 17 years 
was defined as pediatric onset.
Age, age at onset, the presence of  familial IBD, pres-
ence of  extraintestinal manifestations (EIM) including: 
arthritis, conjunctivitis, uveitis, episcleritis, erythema 
nodosum, pyoderma gangrenosum, primary scleros-
ing cholangitis (PSC), and the frequency of  flare-ups 
(frequent flare-up: > 1/year[18]) were registered. Dis-
ease phenotype (age at onset, duration, location, and 
behavior) was determined according to the Montreal 
classification[4] (based on: age at onset, location, and be-
havior, with perianal and upper GI disease as additional 
modifiers). Non-inflammatory behavior was defined as 
either stricturing or penetrating disease. Perianal disease 
and behavior change (from B1 to B2 or B3) or location 
during follow-up was also registered. Every significant 
flare or new symptom was meticulously investigated by 
gastroenterology specialists. Morphological investiga-
tions included proctosigmoidoscopy, colonoscopy, com-
puted tomography (CT) scan, small-bowel ultrasound 
and small bowel X-ray. Patients in clinical remission had 
regular follow-up visits including laboratory and imaging 
studies (annual abdominal ultrasound). Endoscopy and 
CT-scans were only occasionally performed in patients 
in clinical remission. Of  note, upper GI symptoms were 
carefully evaluated. Only indisputable manifestations 
were classified as upper GI involvement (e.g., stenosis, 
ulcers), but not small erosions, or even simple gastric 
or duodenal ulcers, the later occurring shortly after the 
start of  high dose systemic steroid therapy. Upper GI 
endoscopy was performed regularly at the time on the 
diagnosis of  CD only in the last ten years, earlier only in 
case of  gastroesophageal symptoms.
Medical therapy was thoroughly registered (e.g., ste-
roid, immunosuppressive, or biological use, azathioprine 
intolerance as defined by the European Crohn’s and 
Colitis Organization, Consensus Report 28), need for 
surgery or reoperation (resections in CD), development 
of  colorectal and small bowel adenocarcinoma, other 
malignancies, and smoking habits, were investigated by 
reviewing medical records during follow-up and by the 
completion of  a questionnaire. Only patients with a con-
firmed diagnosis for more than one year were enrolled. 
In addition, due to Hungarian health authority regu-
lations, a follow-up visit is obligatory for IBD patients at 
a specialized gastroenterology center every six months. 
Otherwise, under the conditions of  the Hungarian na-
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Table 1  Clinical characteristics of patients with Crohn’s 
disease
CD (n  = 506)
Male/female 251/255
Age at presentation (yr)1 28.5 (22-38)
Follow-up (yr)1  13.5 (6-19.5)
Familial IBD 12.90%
Location at diagnosis
   L1 32.80%
   L2 35.90%
   L3 30.60%
   L4 only   0.70%
   L4   4.80%
Behavior at diagnosis
   B1 56.90%
   B2 19.80%
   B3 23.30%
Frequent relapse 13.10%
Perianal disease 25.50%
Arthritis 26.70%
PSC   1.80%
Ocular   4.70%
Cutaneous   9.30%
Steroid use 68.60%
Azathioprine use 45.80%
Biological use 10.70%
Resection/re-operation 41.3%/28.2%
1Median (interquartile range). L1: Ileal; L2: Colon; L3: Ileocolon; L4: Upper 
gastrointestinal; B1: Inflammatory; B2: Stenosing; B3: Penetrating; PSC: 
Primary sclerosing cholangitis. 
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There was no significant difference in the distribu-
tion of  disease behavior between pediatric (B1: 62%, B2: 
15%, and B3: 23%) and adult onset CD patients (B1: 
56%, B2: 21%, and B3: 23%) at diagnosis (P = NS). In 
addition, the distribution of  disease behavior after 1, 
3, 5, 7, 10 and 15 years and the probability of  develop-
ing penetrating or complicated (stenosing/penetrating) 
disease behavior during follow-up did not significantly 
differ in patients with pediatric and adult onset disease 
by χ 2 and Kaplan-Meier analysis (Figure 1, PLogRank = 
NS, PBreslow = NS) Because the length of  follow-up 
differed between the groups, statistical analysis was not 
performed using final disease behavior data.
Similarly, the probability and time to change in dis-
ease behavior from B1 to B2/B3 disease was not signifi-
cantly different between pediatric- and adult-onset CD 
in a Kaplan-Meier analysis (Figure 2). The probability 
of  complicated disease behavior for patients who ini-
tially exhibited inflammatory disease behavior was 7.6%, 
27.5%, and 42.0% in the pediatric and 12.1%, 26.4%, 
and 37.5% in the adult-onset patients after 1, 5, and 10 
years of  follow-up (PLogRank = NS, PBreslow = NS).
In contrast, the distribution of  disease location at 
diagnosis was different between pediatric- and adult-
onset CD patients (L3 pediatric-onset: 41.3%, vs adult-
onset: 28.8% P = 0.05, Figure 3). A change in disease 
location was observed 8.9% of  the CD patients. The 
probability of  change in disease location was 5.2%, 8.9%, 
and 10.8% after 5, 10, and 15 years of  follow-up, respec-
tively. However, this did not differ according to age at 
onset (PLogRank = NS).
Predictors of progression of disease behavior and 
location 
The calendar year of  diagnosis and location were associ-
ated with presence of  or progress to complicated disease 
behavior at diagnosis and during follow-up. There was 
a significant difference in the distribution of  disease 
behavior in patients diagnosed from 1977 to 1998 (n = 
273, B1: 50%, B2: 22%, and B3: 28%) and from 1999 to 
2008 (B1: 65%, B2: 17% and B3: 18%) at diagnosis (P 
tional health insurance system, patients forfeit their right 
to ongoing subsidized therapy. Consequently, the rela-
tionship between IBD patients and specialists is a close 
one. 
The study was approved by the Semmelweis Univer-
sity Regional and Institutional Committee of  Science 
and Research Ethics and the Csolnoky F Province Hos-
pital Institutional Committee of  Science and Research 
Ethics.
Statistical analysis
Variables were tested for normality by Shapiro Wilk’s 
W-test. The distribution of  disease behavior at different 
time points and between subgroups of  CD patients was 
compared by χ 2-test with Yates correction. Odds ratios 
(OR) were calculated. Kaplan-Meier survival curves were 
plotted for analysis with LogRank and Breslow tests 
to determine probability of  disease behavior change in 
patients with inflammatory (B1) behavior at diagnosis. 
Additionally, Cox-regression analysis using the enter 
method was used to assess the association between cat-
egorical clinical variables and time to disease behavior 
or location change. Variables with a P value < 0.2 in uni-
variate analysis were included in the multivariate testing 
results for continuous variables are expressed as median 
(IQR) unless otherwise stated. Peter Laszlo Lakatos 
performed all statistical analysis. For statistical analysis, 
SPSS® 15.0 (SPSS Inc., Chicago, IL) was used. A P value 
of  < 0.05 was considered significant.
RESULTS
Evolution of disease phenotype in CD patients 
according to age at onset
Five hundred six residents of  the Veszprem province 
were diagnosed with CD during the 32-year period 
from 1977 to 2008. The clinical characteristics of  these 
patients are shown in Table 1. Sixty-five (12.8%) CD 
patients were diagnosed < 17 years of  age. Follow-up in-
formation was collected up to December 31 2009, equal-
ing 5758 patient-years of  follow-up.
1.0
0.8
0.6
0.4
0.2
0.0
Cu
m
ul
at
iv
e 
pr
ob
ab
ili
ty
Penetrating (B3)
Stricturing (B2)
Inflammatory (B1)
1.0
0.8
0.6
0.4
0.2
0.0
Cu
m
ul
at
iv
e 
pr
ob
ab
ili
ty
Penetrating (B3)
Stricturing (B2)
Inflammatory (B1)
BA
Figure 1  The evolution of disease behavior in patients with Crohn’s disease according to the age at diagnosis. A: Pediatric onset; B: Adult onset.
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= 0.003) and after one, three, and five years of  follow-
up (P1-year = 0.007, P3-years = 0.002, P5-years < 0.001 by χ 2 
analysis, and in the probability of  developing penetrating 
or complicated (stenosing/penetrating) disease behavior 
during follow-up in a Kaplan-Meier analysis [PLogRank 
< 0.001, PBreslow < 0.001 (Figure 4)]. The probabilities 
of  penetrating or complicated (stenosing/penetrating) 
disease behavior after three and seven years of  follow-
up were 37.4% and 44.8%, and 58.4% and 66.2%, in the 
1977-1998 cohort, while this was 26.5% and 34.4%, and 
43.6% and 50.6%, in the 1999-2008 cohort.
Trends were similar when pediatric-onset and adult-
onset patients were analyzed separately. The disease 
behavior pattern at diagnosis did not differ significantly 
between the two groups diagnosed in 1977-1998 (pediat-
ric-onset n = 33, B1: 51%, B2: 21%, and B3: 28%, adult-
onset n = 240, B1: 50%, B2: 22%, and B3: 28%) and in 
1999-2008 (pediatric-onset n = 32, B1: 72%, B2: 9%, 
and B3: 19%, adult-onset n = 201, B1: 64%, B2: 18%, 
and B3: 18%). The evolution of  disease behavior was 
also similar to the full cohort (data not shown). 
In addition, disease location and presence of  perianal 
disease was associated with disease behavior at diagnosis 
(colon only B1: 73%, B2: 12%, and B3: 15%, vs ileal in-
volvement B1: 48%, B2: 24%, and B3: 28%, P < 0.001; 
perianal disease absent B1: 66%, B2: 21%, and B3: 13%, 
perianal disease present B1: 30%, B2: 15%, and B3: 
55%, P < 0.001). Probability of  change in disease behav-
ior from B1 to B2/B3 disease was significantly higher 
in patients with ileal involvement (PLogRank = 0.013, 
PBreslow = 0.002, HRL1 or L3 = 2.27, 95%CI: 1.32-3.92) 
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Figure 2  The probability of remaining in inflammatory (B1) disease behavior in patients with Crohn’s disease according to the age at diagnosis (A), loca-
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and perianal disease (PLogRank < 0.001, PBreslow < 
0.001, HRperianal = 2.98, 95%CI: 2.21-4.03) (Figure 2B-D). 
Similarly, need for steroids, either at diagnosis or during 
follow-up, was associated with an increased risk of  dis-
ease progression (PLogRank < 0.001, PBreslow < 0.001, 
HR = 3.66, 95%CI: 1.67-8.04), but not early azathio-
prine exposure. The same trend was observed for smok-
ing (PLogRank = 0.038, PBreslow = 0.051, HRsmoking = 
1.482, 95%CI: 0.96-2.37). 
In contrast, calendar year of  diagnosis was associ-
ated with the progression to non-inflammatory disease 
behavior (PLogRank = 0.04, PBreslow = 0.04, HRafter 
1998 = 0.73, 95%CI: 0.55-0.97) in patients with initially 
inflammatory disease. The probability of  progression to 
complicated disease behavior after five and seven years 
was 15.1% and 21.8% in patients diagnosed after 1998 
while this was 27.4% and 33.3% in patients diagnosed 
between 1977 and 1998. In a multivariate Cox regression 
analysis, after excluding steroid exposure at any time 
point from the variables, the effect of  location (P < 0.001; 
for L1 P < 0.001, HR = 2.19, 95%CI: 1.50-3.09; for L3 
P = 0.01, HR = 1.59, 95%CI: 1.12-2.28), perianal disease 
(P < 0.001, HR = 3.11, 95%CI: 2.23-4.34) and smoking 
(P = 0.031, HR = 1.42, 95%CI: 1.04-1.96) remained sig-
nificant.
Interestingly, the probability of  disease location 
change differed according to smoking status (PLogRank 
= 0.011, PBreslow = 0.03, HRsmoking = 2.35, 95%CI: 
1.19-4.63, Figure 5), but not according to gender, initial 
disease location, behavior, presence of  perianal disease 
or calendar year of  diagnosis.
DISCUSSION
This current, population-based, prospective study re-
veals that evolution of  disease behavior and location do 
not differ significantly between CD patients with adult 
or pediatric onset during long-term follow-up, as the 
change of  disease phenotype is not different significantly 
in pediatric- and adult-onset CD, in contrast to previ-
ous, large, multicenter studies. There were no significant 
differences in disease behavior between pediatric- and 
adult-onset patients at the time of  diagnosis or during 
follow-up. In contrast, findings presented here confirm 
the results of  previous studies, namely, that disease loca-
tion was significantly different according to the age at 
diagnosis. Pediatric patients presented more frequently 
with extensive disease. A change in disease location was 
relatively rare and it was associated with smoking status.
The same, progressive characteristics of  CD were 
described by Cosnes et al[6] in a study of  patients treated 
at a French referral center. More than 80% of  patients 
developed complications with time. After 5 and 20 years’ 
disease duration, the risk for stricturing disease complica-
tions were 12% and 18% respectively, whereas 40% and 
70% of  patients developed penetrating complications, 
respectively. An association was reported, however, with 
disease location; the probability of  complicated disease 
was as high as 94% after 20 years in patients with ileal 
disease. Results were comparable in a Belgian study[5]. In 
this study, 45.9% of  patients had a change in disease be-
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havior after 10 years of  follow-up, especially from non-
stricturing, non-penetrating disease to either stricturing 
(27.1%) or penetrating (29.4%) disease. The frequency 
of  complicated disease was somewhat lower in the pres-
ent population-based study. The probability of  develop-
ing penetrating complications was 35.4% and 58.2% 
after 5 and 20 years’ disease duration, while 55.9% and 
73.7% of  patients diagnosed between 1977-2008 de-
veloped either penetrating or stricturing complications. 
Finally, 53% of  patients developed stricturing or pen-
etrating disease during a 10-year follow-up in the popu-
lation-based prospective IBSEN cohort in CD patients 
diagnosed between 1990 and 1994[8]. Of  note, however, 
in the study by Cosnes et al[6], classification of  patients 
according to disease behavior was a poor predictor of  
disease activity during the next five years. A similar pro-
portion of  patients required immunosuppressive drugs 
and surgery.
According to previous data, the natural history was 
reported to be more severe in pediatric CD. Extensive, 
complicated disease phenotypes were reported to be fre-
quent in a population-based study by Vernier-Massouille 
et al[19] In this study, the prevalence of  B2 and B3 phe-
notypes increased from 25% to 44%, and from 4% to 
15%, while the frequency of  B1 disease decreased from 
71% to 41%, respectively, from diagnosis until approxi-
mately 10 years of  follow-up. In addition, according to 
a recent French study by Pigneur et al[10] patients with 
early childhood-onset onset CD often have more severe 
disease, increased frequency of  active periods, and in-
creased need for immunosuppressants. In contrast, in 
the present study, disease behavior at diagnosis and the 
rate of  progression to complicated disease did not differ 
between pediatric- and adult-onset CD patients. Simi-
larly, in a population-based cohort in New Zealand[3], age 
at diagnosis was not predictive of  the rate of  progres-
sion from inflammatory to complicated disease behavior. 
Until now, this was the only study that investigated the 
importance of  age at onset according to the Montreal 
classification including pediatric onset patients. How-
ever, significant data were collected retrospectively and 
the median follow-up was 6.5 years which is half  of  the 
median follow-up of  patients in the present study. In ad-
dition, > 70% of  CD patients had inflammatory disease 
at diagnosis, with 23% and 40% of  patients with initial 
inflammatory disease progressing to complicated disease 
phenotypes after five and ten years of  follow-up. 
Previous studies suggested that the disease location 
was different between pediatric and adult onset patients 
with more ileocolonic and upper GI disease in pediatric 
patients[3,6,19], in concordance with the present study. In a 
French population-based pediatric CD study[19] the most 
frequent location at diagnosis was ileocolonic disease 
(63%). Disease extension was observed in a surprisingly 
large proportion of  pediatric patients (31%) during fol-
low-up. In addition, in a population-based New-Zealand 
CD cohort, authors have reported an association be-
tween initial disease location and probability of  disease 
extension. Patients with colon-only location progressed 
more rapidly to ileocolonic disease than those with ileal 
disease (P = 0.02). Of  note, the rate of  disease location 
change at 10 years in this study (9%) was in the range 
reported in the present study (8.9% during a median 13 
years), although somewhat higher rates were reported in 
the study by Louis et al[5] (15.9%  during 10-years). In the 
latter study, 20.3% of  patients with an initial L1 location 
changed to another location, while the proportion of  pa-
tients changing from L2 was 16.7%. In the present study, 
the probability of  disease behavior change was 8.8% and 
10.9% after 10 and 15 years of  disease duration. The 
change in disease location was not different between pa-
tients with pediatric or adult onset, nor between patients 
with L1 and L2 disease. In contrast, a novel finding of  
the present study was that change in disease location was 
associated with smoking status (HR = 2.35, P = 0.01). 
The probability of  a change in disease location was 5.8% 
and 5.8% in non-smokers, and 11.7% and 15.1% in 
smokers after 10 and 15 years’ disease duration.
Additional predictors of  disease behavior change 
identified in the present study included presence of  ileal 
involvement, perianal disease, smoking and calendar year 
of  diagnosis, with perianal involvement being the most 
important predictor. The role of  initial ileal involvement, 
extensive disease, and perianal disease as a possible pre-
dictor of  non-inflammatory behavior was first suggested 
in a landmark study by Cosnes et al[6]. Additionally age 
< 40 years at diagnosis was associated with the develop-
ment of  penetrating complications (HR = 1.3). Similar 
findings were presented from the New Zealand cohort[3], 
where patients with ileal (L1) disease progressed most 
quickly to non-inflammatory disease behavior, followed 
by patients with upper GI (L4) or ileocolonic (L3) dis-
ease (P < 0.0001). The probability of  progression to 
penetrating disease was similar to that of  progression to 
stenosing disease after 10 years. Overall, the proportion 
of  penetrating disease was highest in those with ileoco-
lonic (27%) or ileal disease (21%) compared to patients 
with colon-only disease (7%, P = 0.006). Patients with 
perianal disease were at risk of  a change in disease be-
havior (HR = 1.62, 95%CI: 1.28-2.05). In a subsequent 
population-based study from the IBSEN group[8], non-
inflammatory disease behavior during follow-up was 
associated with initial L1 (86%) vs L2 (30%, P < 0.001) 
or L3 location (60%, P < 0.005). Finally, in a previous 
publication by our group[7], ileal disease location (HR 
= 2.13, P = 0.001), presence of  perianal disease (HR = 
3.26, P < 0.001), prior steroid use (HR = 7.46, P = 0.006), 
early AZA (HR = 0.46, P = 0.005) and smoking (HR = 
1.79, P = 0.032) were independent predictors of  disease 
behavior change in a referral CD cohort. Data regarding 
the effect of  smoking are equivocal, however. A recent 
review[20] and previous studies have demonstrated that 
smoking was associated with complicated disease, pen-
etrating intestinal complications[21], and greater likelihood 
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of  progression to complicated disease, as defined by de-
velopment of  strictures or fistulae, a higher relapse rate, 
and need for steroids and immunosuppressants[22]. In a 
recent study by Aldhous et al[23], the deleterious effect of  
smoking was only partially confirmed. Current smoking 
was associated with less colonic disease, however smok-
ing habits at diagnosis were not associated with time to 
development of  stricturing, penetrating disease, nor with 
perianal penetrating disease or time to first surgery. Of  
note, a possible neutralizing effect of  immunosuppres-
sant therapy was reported in some studies[24,25].
Conclusions were slightly different if  authors as-
sessed the factors associated with the development of  
disabling disease. In the paper by Loly et al[26] strictur-
ing behavior at diagnosis (HR = 2.11, P = 0.0004) 
and weight loss (> 5 kg) at diagnosis (HR = 1.67, P = 
0.0089) were independently associated with time to the 
development of  severe disease in multivariate analysis. 
The definition of  severe, non-reversible damage was, 
however, much more rigorous. It was defined by the 
presence of  at least one of  the following criteria: the 
development of  complex perianal disease, any colonic 
resection, either two or more small-bowel resections or 
a single small-bowel resection measuring more than 50 
cm, or the construction of  a definite stoma. In a similar 
study by Beaugerie et al[27], with a different definition of  
disabling disease, initial requirement for steroid use (OR 
= 3.1, 95%CI: 2.2-4.4), an age below 40 years (OR = 2.1, 
95%CI: 1.3-3.6), and the presence of  perianal disease 
(OR = 1.8, 95%CI: 1.2-2.8) were associated with the de-
velopment of  disabling disease[27]. The positive predictive 
value of  disabling disease in patients with two and three 
predictive factors of  disabling disease was 0.91 and 0.93, 
respectively. Concordantly, in the present study, need for 
steroids was identified as a risk factor for progression of  
disease behavior (HR = 3.66, P < 0.001).
Finally, the calendar year of  diagnosis was associated 
with disease behavior at diagnosis and the progression to 
non-inflammatory disease behavior (PLogRank = 0.04, 
PBreslow = 0.04, HR1after 1998 = 0.73, 95%CI: 0.55-0.97) 
in patients with initially inflammatory disease in the pres-
ent study, suggesting a change in the natural history of  
the disease in the last decade. Trends were similar in the 
pediatric- and adult-onset patients. However, although 
azathioprine was started more frequently and earlier in 
the last decade[28], the change in disease behavior pro-
gression was not directly associated with the increased 
and earlier use of  azathioprine, pointing to the fact that 
probably the change in the patient management is far 
more complex. Of  note, distribution of  disease location 
was not different in patients with a diagnosis before or 
after 1998. In contrast, presence of  perianal disease was 
less prevalent in the later group (17.9% vs 31.5%, P < 
0.001, OR = 0.48), suggesting and increased awareness 
and probably earlier diagnosis.
Authors are aware of  possible limitations of  the pres-
ent study. The treatment and monitoring paradigm for 
CD patients has changed significantly over the last three 
decades. The majority of  patients received maintenance 
therapy with sulfasalazine or a 5-aminosalicylic acid de-
rivative (mesalazine or olsalazine), if  tolerated, especially 
until the mid-1990s. Azathioprine or 6-mercaptopurine 
were used as maintenance therapy for steroid dependent, 
steroid-refractory, or fistulizing patients in selected cases, 
mainly after resective surgery until the late-1980s, but 
on a more widespread basis and earlier in the disease 
course only from the mid-to-late 1990s. Short-term oral 
corticosteroid treatment was used for clinical exacerba-
tions, usually at initial doses of  40-60 mg of  prednisone 
per day, which was tapered and discontinued over 2 to 
3 mo. Infliximab (and later adalimumab) has been used 
for both induction and maintenance therapy in selected 
cases since the late 1990s. Similarly, small-bowel follow 
through was replaced by CT or MR-enterography from 
the 1990s. The strengths of  the study include long-term 
prospective follow-up, the fact that leading IBD special-
ists were involved during the entire follow-up, and also 
that the evaluation and monitoring of  pediatric-onset 
patients was managed jointly by pediatric and adult gas-
troenterologists using similar principles. 
In conclusion, the long-term evolution of  disease be-
havior in pediatric- and adult-onset CD patients did not 
differ in this population-based incident cohort. In con-
trast location, smoking, and need for steroids were asso-
ciated with presence of, or progression to, complicated 
disease behavior at diagnosis and during follow-up, in 
concordance with previous referral and population-based 
studies. In addition, there was a change in the evolution 
of  the disease behavior according to the calendar year of  
diagnosis. Progression to complicated disease phenotype 
was less likely in patients diagnosed after 1998, however 
this was at least partly associated with a milder disease 
phenotype at diagnosis including a decreased prevalence 
of  perianal disease in the later group. A novel finding of  
the present study was that the change in disease location 
was associated with smoking status.
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According to the available literature, pediatric onset Crohn’s disease (CD) runs 
a more aggressive course, including more extensive disease location, more up-
per gastrointestinal involvement, growth failure, more active disease, and need 
for more aggressive medical therapy, in predominantly referral-center studies. 
Research frontiers
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evolution of disease behavior was not different in pediatric- and adult-onset 
CD patients in this prospective population-based incident cohort from Eastern 
Europe. Interestingly, change in disease location was associated with smoking 
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Terminology
Disease phenotype is categorized according to the Montreal classification and 
includes age at onset (A1: < 17 years, A2: 17-40 years and A3: > 40 years) 
location (L1: Ileal, L2: Colon, L3: Ileocolon, L4: Upper gastrointestinal) and 
behavior (B1: Inflammatory, B2: Stenosing, B3: Penetrating). While disease lo-
cation is thought to be more stable, a change in the disease behavior is a rather 
frequent event.  
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with CD reporting that the risk for developing complicated disease phenotype is 
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